# A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia

> **NCT06916793** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 288 (estimated)

## Conditions studied

- Androgenetic Alopecia

## Interventions

- **DRUG:** CKD-843 dose#1
- **DRUG:** CKD-843 dose#2
- **DRUG:** Placebo of CKD-843 dose
- **DRUG:** Dutasteride Capsules
- **DRUG:** Placebo of Dutasteride Capsule

## Key facts

- **NCT ID:** NCT06916793
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-04-30
- **Primary completion:** 2026-12-19
- **Final completion:** 2027-09-17
- **Target enrollment:** 288 (ESTIMATED)
- **Last updated:** 2025-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06916793

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06916793, "A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT06916793. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*